Status:
COMPLETED
Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.
Lead Sponsor:
ViiV Healthcare
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
HIV Infections
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and extent of elimination, safety and tolerability of a single oral dose of \[14C\] BMS-955176 in healthy male subj...
Eligibility Criteria
Inclusion
- Healthy Male subjects
- Ages 18-50 years
- Body weight of at least 110 lbs (50kg)
- BMI of 18 to 32 kg/m\^2
- non-smoking
Exclusion
- Clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months (eg serial X-ray or CAT scans, barium meals).
- gastrointestinal disease including gastrointestinal surgery
- constipation or irregular bowel movements
Key Trial Info
Start Date :
August 8 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 9 2014
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT02206711
Start Date
August 8 2014
End Date
September 9 2014
Last Update
April 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Madison, Wisconsin, United States, 53704